- Report
- February 2025
- 200 Pages
Global
From €4285EUR$4,490USD£3,590GBP
- Report
- March 2025
- 89 Pages
Global
From €5345EUR$5,600USD£4,478GBP
- Report
- August 2024
- 200 Pages
Global
From €2376EUR$2,490USD£1,991GBP
- Report
- May 2024
- 133 Pages
Global
From €6203EUR$6,499USD£5,197GBP
- Report
- May 2024
- 133 Pages
Global
From €6203EUR$6,499USD£5,197GBP
- Drug Pipelines
- April 2024
- 90 Pages
Global
From €1909EUR$2,000USD£1,599GBP
- Report
- September 2024
- 343 Pages
Global
From €7587EUR$7,950USD£6,357GBP
- Clinical Trials
- April 2024
- 220 Pages
Global
From €2386EUR$2,500USD£1,999GBP
- Drug Pipelines
- April 2024
- 60 Pages
Global
From €1909EUR$2,000USD£1,599GBP
- Clinical Trials
- April 2024
- 80 Pages
Global
From €1909EUR$2,000USD£1,599GBP
- Drug Pipelines
- August 2024
- 150 Pages
Global
From €2662EUR$2,789USD£2,230GBP
- Report
- March 2022
- 144 Pages
Global
From €10975EUR$11,500USD£9,196GBP
- Report
- November 2021
- 101 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- November 2023
- 30 Pages
Global
From €3102EUR$3,250USD£2,599GBP
- Report
- August 2022
- 161 Pages
Global
From €7158EUR$7,500USD£5,997GBP
- Report
- April 2023
- 115 Pages
Global
From €4533EUR$4,750USD£3,798GBP
- Report
- August 2022
- 541 Pages
Global
From €2386EUR$2,500USD£1,999GBP
- Report
- April 2022
- 48 Pages
Global
From €1909EUR$2,000USD£1,599GBP

Dupilumab is a monoclonal antibody used to treat respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). It works by blocking the action of a protein called interleukin-4 (IL-4) and interleukin-13 (IL-13), which are involved in inflammation. Dupilumab is approved for use in adults and adolescents aged 12 years and older with moderate-to-severe asthma, and for adults with moderate-to-severe COPD. It is administered as an injection under the skin.
Dupilumab is a relatively new drug, and is the first biologic therapy approved for the treatment of asthma and COPD. It has been shown to reduce symptoms and improve lung function in patients with these conditions. It is also being studied for use in other respiratory diseases, such as eosinophilic asthma and bronchiolitis obliterans syndrome.
Some companies in the Dupilumab market include Regeneron Pharmaceuticals, Sanofi, and AstraZeneca. Show Less Read more